M&A / Deals AbbVie climbs post-Allergan M&A peak with Apogee buy PharmaphorumAbbVie has announced its biggest acquisition since the $63 billion merger with Allergan, buying Apogee and its 'mega-blockbuster' immunology pipeline.Immunology & InflammationRead full story pharminent June 22, 2026 (Last updated: June 22, 2026) Pharmaphorum AbbVie has announced its biggest acquisition since the $63 billion merger with Allergan, buying Apogee and its ‘mega-blockbuster’ immunology pipeline. Immunology & Inflammation Read full story Post navigation Previous: Lilly bets up to $800M for BioArctic’s brain delivery techNext: Pfizer drug acquired in Seagen deal disappoints in lung cancer study Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026